Document is current
Any future updates will be listed below
-
Authors
Serneels, Lutgarde
Sierksma, Annerieke
Pasciuto, Emanuela
Geric, Ivana
Nair, Arya
Martinez-Muriana, Anna
Snellinx, An
De Strooper, Bart
-
Funding
Funding for this research was provided by:
FBRI (Generation and initial characterization of a humanized CSF1 Knock in model to study microglia function and dysfunction)
HORIZON EUROPE European Research Council (ERC-834682 CELLPHASE_AD)
Dementia Research UK (MR/Y014847/1)
KU Leuven (Methusalem grant)
Fonds Wetenschappelijk Onderzoek
Vlaams Instituut voor Biotechnologie
Leuven Univeristair Fonds (The opening the future campaign)
The Belgian Alzheimer Research Foundation
Alzheimer's Association
Bax-Vanhuffelen Chair for AD
Queen Elisabeth Medical Foundation
- License Information
-
More Information
Article History
Received: 15 November 2024
Accepted: 2 March 2025
First Online: 11 March 2025
Declarations
:
: All animal experiments were conducted according to protocols approved by the local Ethical Committee of Laboratory Animals of KU Leuven (P125-2022). The use of human ESC (H9) and iPSC (UKBi011-A-3) are approved by the local Ethical Committee of UZ Leuven (S63481).
: Not applicable.
: B.D.S. is or has been a consultant for Eli Lilly, Biogen, Janssen Pharmaceutica, Eisai, AbbVie and other companies. B.D.S is also a scientific founder of Augustine Therapeutics and a scientific founder and stockholder of Muna Therapeutics. I.G. and A.N. are currently employees at Muna Therapeutics.
